12/07/15 - 06:27 AM EST
Bluebird Bio is going to have a rough Monday because of the disappointing gene therapy data presented over the weekend at the American Society of Hematology annual meeting.
12/06/15 - 09:36 AM EST
Expanded results from a Global Blood study continue to show encouraging reductions in the number of sickled red blood cells, supported by other improvements in measures of the disease.
12/06/15 - 09:01 AM EST
Bluebird's challenge is to understand why exemplary results seen in a single French sickle cell patient are not being duplicated in the three other sickle cell patients treated more recently.
12/05/15 - 01:09 PM EST
Modified donor T cells and a molecular "safety switch" developed by Bellicum Pharmaceuticals improved the safety and outcome of stem cell transplants performed on children suffering from rare blood diseases.
12/05/15 - 10:39 AM EST
U.S. researchers using a personalized therapy made from genetically engineered T cells induced remissions in some patients with highly advanced multiple myeloma, a type of blood cancer affecting plasma cells.
12/02/15 - 01:43 PM EST
Zafgen shares plunge on concerns regulators could step in to halt clinical development of the company's obesity drug for patient-safety reasons.
12/02/15 - 06:11 AM EST
TheStreet's biotech columnist Adam Feuerstein answers readers' questions about health care.
11/25/15 - 06:49 AM EST
I give BioMarin a 5% chance of winning approval for drisapersen from the FDA following a negative advisory panel. I might be too generous.
11/24/15 - 07:39 AM EST
A panel of outside experts convened by the U.S. Food and Drug Administration will spend all day Tuesday reviewing drisapersen, BioMarin's experimental drug for Duchenne muscular dystrophy (DMD).
11/21/15 - 11:30 AM EST
The last thing the biotech industry needs today is another hit to investor credibility. Clovis isn't helping.